GLP-1 agonists compared: Semaglutide, Tirzepatide, Retatrutide

The incretin field moved from a single-receptor target to dual and now triple receptor agonism in roughly fifteen years of published research. Semaglutide established the GLP-1 receptor monotherapy framework in metabolic literature. Tirzepatide added simultaneous GIP receptor co-activation. Retatrutide added the glucagon receptor as a third target. Each generation produced different magnitudes and different research-endpoint profiles in the published trials.

This article is a structured side-by-side of the three compounds — identifiers, receptor targets, half-life characteristics, and the categories of published peer-reviewed research that have investigated each. Everything is research-frame language. No protocol guidance. No clinical recommendations.

Quick reference

Property	Semaglutide	Tirzepatide	Retatrutide
Receptor target(s)	GLP-1R	GIP-R + GLP-1R	GIP-R + GLP-1R + GCG-R
Generation	Single agonist	Dual agonist	Triple agonist
CAS number	910463-68-2	2023788-19-2	2381089-83-2
Molecular formula	C187H291N45O59	C225H348N48O68	C221H343N51O59
Molecular weight	4113.58 g/mol	4813.45 g/mol	4731.41 g/mol
Length	31 aa (modified)	39 aa (modified)	39 aa (modified)
Half-life (research models)	~165 h	~120 h	~108–144 h
Active research focus	Glycemic control, body composition, satiety signaling	Combined GIP/GLP-1 effects, lipid metabolism, weight reduction in research models	Triple-axis metabolism, hepatic energy expenditure, large body-composition changes in trials

The single → dual → triple progression

Semaglutide entered the published metabolic literature as a refined, long-acting GLP-1 receptor agonist with structural modifications (Aib⁸ substitution, fatty-acid side chain via spacer) that resist DPP-4 enzymatic degradation. The longer half-life enabled once-weekly research designs in animal and human trial literature [1].

Tirzepatide added a second receptor target. Co-activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor alongside GLP-1 produced research outcomes in published trials that exceeded GLP-1-only comparators on body-weight and HbA1c endpoints. The published mechanism literature documents complementary GIP/GLP-1 signaling — GIP affecting adipose tissue and lipid handling, GLP-1 affecting satiety signaling and beta-cell response [2].

Retatrutide extends the multi-agonist framework to three targets — GIP, GLP-1, and the glucagon receptor (GCG-R). The glucagon-axis component activates hepatic energy expenditure pathways in research models. Published phase-2 trial literature has reported the largest body-weight changes seen in this peptide class [3].

Receptor targets — what each axis does in research

• GLP-1 (glucagon-like peptide-1) receptor: the foundational target. Activates beta-cell insulin response, inhibits glucagon (when blood glucose is elevated), slows gastric emptying, and modulates central satiety pathways. Underlies the body-weight and HbA1c effects across all three compounds in published research.
• GIP (glucose-dependent insulinotropic polypeptide) receptor: sister incretin to GLP-1. In adipose-tissue research literature it appears to modulate lipid storage and energy partitioning. Tirzepatide and Retatrutide both engage this receptor, layered on top of GLP-1 activity.
• Glucagon receptor: classically the counter-regulatory hormone to insulin. In Retatrutide research the agonism is a net effect — combined with strong GIP/GLP-1 activity, glucagon engagement appears to drive hepatic energy expenditure in published trial literature without producing the glucose-elevating effects glucagon would cause in isolation.

The progression from single to triple is not just “more is better.” Each added axis interacts with the others. The published literature on Tirzepatide and Retatrutide is what demonstrates which combinations produce additive or synergistic outcomes in research-model endpoints versus where additional agonism plateaus.

Half-life and dosing-frequency hypotheses in research

All three compounds share the same general half-life-extension strategy: fatty-acid side chains linked via a glutamic-acid spacer to a key residue, enabling reversible binding to serum albumin. Albumin binding shields the peptide from glomerular filtration and slows clearance — producing the long half-lives that distinguish this class from earlier short-acting GLP-1 research compounds.

Semaglutide’s half-life of ~165 hours in published research models is the longest of the three. Tirzepatide is roughly ~120 hours. Retatrutide trial literature reports approximately ~108–144 hours depending on model and dose. All three support once-weekly administration in research-design literature.

Published research focus per compound

Semaglutide has the deepest published-trial corpus — multi-year diabetes-control studies, cardiovascular-outcome research, body-composition investigation, hepatic-fat research. As the foundational GLP-1 monotherapy, it serves as the comparator arm in many trials of the newer compounds.

Tirzepatide published research has concentrated on head-to-head comparisons against Semaglutide and other GLP-1 monotherapies (e.g., the SURPASS and SURMOUNT trial programs). The literature reports incremental endpoint magnitudes versus single-agonist comparators on body-weight and HbA1c.

Retatrutide is the newest of the three. Published phase-2 trial literature focuses on body-composition endpoints and metabolic-rate outcomes attributable to glucagon-axis activation. Long-term outcome research is still emerging.

Storage and handling

All three compounds ship as lyophilized powder. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window — typically 24+ months under proper storage for this class.
• Reconstituted state: bacteriostatic water (0.9% benzyl alcohol) is the standard diluent. Refrigerate at 2–8°C after reconstitution. Research-handling literature for albumin-binding GLP-1 analogues suggests use within ~4 weeks of reconstitution under refrigerated conditions.
• BAC water enables multi-puncture vials — the preservative inhibits microbial growth across repeated access in research protocols, typically up to ~28 days under refrigeration.
• Avoid freeze-thaw cycles after reconstitution. The peptide-albumin reversible binding is sensitive to repeated phase changes; published handling guidance for this class recommends single freeze and refrigerated storage thereafter.

Each TogoPeptide shipment includes a per-batch Certificate of Analysis — HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, analysis date.

Practical research-supply considerations

From a research-supply standpoint:

• Vial strengths: Semaglutide ships in 2 mg / 5 mg / 10 mg lyophilized vials. Tirzepatide in 5 mg / 10 mg / 15 mg / 20 mg / 30 mg / 60 mg. Retatrutide in 5 mg / 10 mg / 20 mg / 30 mg.
• Reconstitution math: all three require careful per-mg dilution. Use the reconstitution calculator to compute the diluent volume per target research concentration.
• Cross-class research designs: if comparing GLP-1 vs dual vs triple agonism in a single research model, request matching lot numbers at order time so that batch-to-batch identity confirmation is documented across all arms.
• Curated stack: the Fat-Loss Stack bundles Tirzepatide, Semaglutide and Retatrutide with bacteriostatic water and syringes for combined research-supply orders.

Closing — what this comparison does and doesn’t say

This article documents what published peer-reviewed research has investigated for Semaglutide, Tirzepatide and Retatrutide. It is structural and progression-context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

If you’re sourcing any of these compounds for laboratory research:

• Open the Semaglutide product page for full identifiers, variants, and per-batch COA
• Open the Tirzepatide product page for the same
• Open the Retatrutide product page for the same
• Or browse all fat-loss research compounds in one place

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.